Federica Vincenzi

Mrs. Federica Vincenzi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2024 in Viruses
Verified
Journal Article
Open access
PDF file
CSCarlo Smirne
Carlo Smirne
MCMaria Crobu
Maria Crobu
ILIrene Landi
Irene Landi
NVNicole Vercellino
Nicole Vercellino
DADaria Apostolo
Daria Apostolo
Mario PirisiMario Pirisi
Mario Pirisi
Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection through antiviral regimes. Currently, highly effective direct-acting antivirals (DAAs) offer extraordinary success across all patient categories, including cirrhotics. Despite these advancements, recent studies have reported that even after sustained virologic response (SVR), individuals with advanced liver disease/cirrhosis at the time of DAA treatment may still face risks of HCC occurrence or recurrence. Based on this premise, this review tries to shed light on the multiple mechanisms that establish a tumorigenic environment, first, during chronic HCV infection and then, after eventual viral eradication by DAAs. Furthermore, it reviews evidence reported by recent observational studies stating that the use of DAAs is not associated with an increased risk of HCC development but rather, with a significantly lower chance of liver cancer compared with DAA-untreated patients. In addition, it seeks to provide some practical guidance for clinicians, helping them to manage HCC surveillance of patients who have achieved SVR with DAAs.

Verified
Journal Article
Open access
PDF file
FVFederica Vincenzi
Federica Vincenzi
CSCarlo Smirne
Carlo Smirne
STStelvio Tonello
Stelvio Tonello
PSPier Paolo Sainaghi
Pier Paolo Sainaghi
Vitamin D is a steroid hormone whose relevant immunomodulatory role has been widely described. Therefore, its contribution to the pathogenesis of immune-mediated diseases is an important and ongoing matter of research. Specifically, the active form of vitamin D, i.e., 1,25-dihydroxyvitamin D, through the interaction with its receptor, exerts different activities on the innate and adaptive immune system, among which are suppression of inflammation and promotion of tolerogenic responses. Indeed, vitamin D insufficiency/deficiency has been related to the pathogenesis and/or disease activity of several autoimmune diseases, including, amongst others, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes mellitus. Based on these premises, in this review, we will describe the main molecular mechanisms modulated by vitamin D in the regulation of immune responses, including the induction of immune tolerance. Moreover, we will focus on the current knowledge regarding the contribution of vitamin D depletion to the aforementioned autoimmune diseases, seeking to provide evidence as to why its supplementation in the context of these immune-mediated disorders may potentially ameliorate disease activity and its related clinical manifestations.

14 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
STStelvio Tonello
Stelvio Tonello
DDDavide D'Onghia
Davide D'Onghia
ARAnnalisa Di Ruscio
Annalisa Di Ruscio
SMSilvia Maria Mora
Silvia Maria Mora
FVFederica Vincenzi
Federica Vincenzi
PSPier Paolo Sainaghi
Pier Paolo Sainaghi
Introduction: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are severe complications of patients with systemic sclerosis (SSc). Currently, there are a few tests for early identification of these conditions, although they are invasive and time-consuming. Extracellular vesicles (EVs) offer a promising possibility for gathering information on tissue health. This study aims to characterize EVs in cases of systemic sclerosis complicated by pulmonary hypertension and pulmonary fibrosis. Methods: A cohort of 58 patients with SSc was evaluated, including 14 with pulmonary hypertension, 17 with pulmonary fibrosis, and 27 without complications. Additionally, 11 healthy subjects, matched for sex and age, served as a control group. EVs were characterized by using a MACSplex kit to analyze the expression of 37 membrane markers. Results: After the overall analysis, we show that EVs from SSc patients had higher expression of CD146, CD42a, and CD29 (p = 0.03, p = 0.02 and p = 0.05) but lower expression of HLA-ABC with respect to the control patients (p = 0.02). Multivariate analyses demonstrated that only CD42a has a significant association with the disease (p = 0.0478). In group comparative analyses (PAH, ILD, uncomplicated systemic sclerosis (named SSc no PAH no ILD), and controls), CD3 and CD56 were higher in PAH patients, with respect to the controls, ILD, and the group SSc no PAH no ILD (CD3: p = 0.01, p = 0.003, p = 0.0005; CD56: p = 0.002, p < 0.0001, p = 0.0002). HLA-DR showed higher expression in PAH patients with respect to ILD patients (p = 0.02), CD25 showed higher expression in PAH patients with respect uncomplicated SSc (p = 0.02), and CD42a showed higher expression in PAH patients with respect to the controls (p = 0.03); nevertheless, multivariate analyses demonstrated that only CD3 retained its association with PAH. Conclusions: The expression of CD42a, a platelet-derived marker indicating endothelial damage, suggests its potential to provide information on the state of the microcirculation in systemic sclerosis. The higher expression of CD3 on the surface of the EVs in PAH patients might indicate increased T-cell activity in tissues, with a possible association with the development of pulmonary hypertension.

Verified
Journal Article
Open access
PDF file
MRManuela Rizzi
Manuela Rizzi
FVFederica Vincenzi
Federica Vincenzi
STStelvio Tonello
Stelvio Tonello
EREleonora Rizzi
Eleonora Rizzi
GCGiuseppe Francesco Casciaro
Giuseppe Francesco Casciaro
PSPier Paolo Sainaghi
Pier Paolo Sainaghi
Research into effective predictive markers and therapeutic interventions for COVID-19 remains of considerable interest. Vitamin D may be relevant, especially in frail populations in whom deficiency is more prevalent. In this prospective observational cohort study, 139 patients with moderate-to-severe COVID-19 who were hospitalized during the third wave of the pandemic in Italy were enrolled. Plasma vitamin D concentrations (both 25-hydroxyvitamin D-25(OH)D and 1,25-dihydroxyvitamin D-1,25(OH)2D) together with parathyroid hormone levels were measured using a chemiluminescent assay validated for clinical use on automated laboratory platforms. Plasma vitamin D levels were below the sufficiency threshold. Notably, 25(OH)D concentrations were significantly lower in patients who experienced a negative outcome (11.10 [8.80–16.20] vs. 15.25 [9.90–24.80] ng/mL, p = 0.0450) and significantly higher in patients with rapid clinical recovery (15.25 [10.70–24.80] vs. 13.30 [7.47–19.60] ng/mL, p = 0.0446) compared with all other patients. Through multivariable logistic regression analysis, higher 25(OH)D levels at the time of hospitalization were confirmed as an independent predictor of favorable outcome. A plasma 25(OH)D concentration above 11.10 ng/mL predicted favorable disease resolution, with a positive likelihood ratio of 1.40 (IQR: 1.05–1.87). In conclusion, our findings support plasma vitamin D levels as an independent predictor of clinical outcomes in patients hospitalized with COVID-19 pneumonia.

19 June 2026 in European Journal of Internal Medicine
Verified
Journal Article
Open access
PSPier Paolo Sainaghi
Pier Paolo Sainaghi
MRManuela Rizzi
Manuela Rizzi
STStelvio Tonello
Stelvio Tonello
FVFederica Vincenzi
Federica Vincenzi
MPMarco Primatesta
Marco Primatesta
FGFrancesco Gavelli
Francesco Gavelli
Early prognostic stratification of septic patients at hospital admission is challenging, especially in the elderly. Considering the well-known immunomodulatory effects of vitamin D and its common deficiency among elderly, we aimed to evaluate if vitamin D plasma levels (25(OH)D) at hospital admission could be a prognostic biomarker in septic patients. Secondary analysis of data and samples from the multicenter Need-Speed trial, a multicenter study involving the emergency and internal medicine wards of five Italian hospitals. 1132 consecutive patients admitted to hospital with suspected sepsis were enrolled. 859 were confirmed to have sepsis at the end of the diagnostic work-up and 829 patients were included in the analysis. 25(OH)D at admission was measured using an automated chemiluminescence assay. Among the 829 patients included (median age 81 years [IQR: 72-87]), severe hypovitaminosis D was observed (median 11.2 ng/mL [IQR: 8.0-19.4]). At univariate analysis, baseline 25(OH)D levels were significantly lower in patients who died at 30 and 90 days and higher among patients discharged alive within 15 days (p < 0.05). Multivariate models confirmed 25(OH)D as an independent predictor of 90-day mortality and of discharge alive at 15 days (p < 0.05). Moreover, a 25(OH)D threshold of 12 ng/mL independently predicted both survival at 90 days (OR: 0.5961 [0.4068-0.8735]) and discharge alive at 15 days (OR: 1.6055 [1.1738-2.1960]). Lower 25(OH)D levels were independently associated with poorer clinical outcomes in older patients with sepsis. Therefore, hypovitaminosis D assessment may provide prognostic value beyond validated risk stratification tools, warranting prospective validation.

25 August 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
FVFederica Vincenzi
Federica Vincenzi
MCMaria Crobu
Maria Crobu
STStelvio Tonello
Stelvio Tonello
NVNicole Vercellino
Nicole Vercellino
Elena GrossiniElena Grossini
Elena Grossini
CSCarlo Smirne
Carlo Smirne
Viral infections are a widely recognized cause of mortality. Recently it has been demonstrated that vitamin D plays an important immuno-modulatory role in both innate and adaptive immune responses against infections, by reducing excessive inflammation and enhancing defense mechanisms. Specifically, exacerbation of infections may cause sepsis, characterized by a dysregulated immune response with hyperinflammation and immune exhaustion. Vitamin D can modulate these processes through various mechanisms, such as enhancing antiviral protection, promoting anti-inflammatory responses, protecting endothelial barriers, and modulating T-cells. This has been demonstrated for various viral infections, including influenza viruses, respiratory syncytial virus, and severe acute respiratory syndrome coronavirus. Although vitamin D deficiency has been associated with increased susceptibility to viral infections and immune cells of infected patients are highly responsive to vitamin D, the clinical benefits of its supplementation to vitamin D-deficient infected individuals are uncertain and, most importantly, direct evidence linking vitamin D to viral sepsis specifically remains particularly limited, with most mechanistic inference extrapolated from non-septic viral infection and bacterial sepsis literature. Based on these assumptions, this review will outline the present understanding about vitamin D regulatory effects on immune system and the possible connection between its serum levels and viral infections, while also addressing controversial issues.